SCYNEXIS (SCYX) 15 Aug 222022 Q2 Earnings call transcript

Ladies and gentlemen, good morning, and welcome to SCYNEXIS, Inc.

Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. the to turn now will conference Ms. over I Relations. Etchison, Communications Investor and Debbie Please go ahead.

everyone, today’s corporate welcome discuss you. and Thank Hello, to quarter financial our XXXX conference results and update. second to call

on furnished the under subsequently XX-K only XXXX. August XX, XX-Q, and caption filed the SCYNEXIS me actual another remind All based as and of to outlook quarterly results operational future statements are promotional expressed today, expectations, statements for call to with Before sufficient Commission. we to future, current business Securities start, in and you subject today’s not no made. Risk reflect strategy. report to or occur each The with most including Exchange forward-looking document uncertainties, in Report case or as Form Form our expectations from such Factors, include on risks Because speak and recent our call the concerning including differ that such statements they after well statements those on on that such on financial for may exist information prescribing today’s undertakes decisions. and events or leadership’s circumstances performance, forward-looking the statements materially our for that statements. including were the our Securities by implied as Commission, not forward-looking Annual will Please to financial intended date Exchange update refer purposes obligation and our let which filings for is

Commercial Officer, Officer, Officer, Chief SCYNEXIS President Interim Larry and Hoffman. us Dr. Dr. Chief are Taglietti; and Medical CEO, Joining Coyne; today’s Chief Financial Marco Christine David Angulo; call

the remarks, questions. your prepared we’ll call to our Following open

and the Dr. Now, call CEO. over President to I will Taglietti, Marco turn

here our Thank you, nicely Thank investor are call. today everyone. Things morning, for quarter moving for you forward SCYNEXIS. Debbie. at XXXX us of second earnings joining Good

built by new by the We urgency. unpredictability achieving standalone And the only in are use XX adoption of record antifungals in BREXAFEMME drug continuing marked development of sector seen by the companies, anti-infective We summer. and launched first a of name leading last we but of now years, despite class solid the utmost progress and not a the approval toward steady over ibrexafungerp have one environment. track the labeling with ibrexafungerp. BREXAFEMME of macro a headwinds the to brand We expanding of

long-lasting Finally, well we to upcoming antifungal And are of execute have number our catalysts we broad, building on beyond. and capitalized XXXX goal a of a franchise. in

SCYNEXIS move to onward. continue We

accomplishments of the indication. VVC recurrent both, FDA to only to supplemental additional summarize me will second treatment indication, only, application of November for VVC. of key If quarter. approved this of prescription be confidence drug BREXAFEMME to a and payers is few for date anti-fungal both, approved a prevention the of increased prescribers, commercial labeling has PDUFA growth. Let and critical second strategy briefly build and the include BREXAFEMME our drive with piece a This the VVC our assigned XXXX expand XX, new for recurrent

VANQUISH the fluconazole regard Xb treating in ibrexafungerp’s ibrexafungerp patients most respond in date. results candidiasis goal enrollment you don’t who Phase VVC treatment. the study the started of and Dr. provide will has to challenging demonstrate efficacy Chief to Medical hospital top-line trial David in also this have the potential We XXXX. study by our with results patients. invasive details on further Angulo, in to started of of expected the With and indications, positive end oral is The for this approval VVC MARIO to more XXXX program Officer,

what quarter in over of net revenues we in the BREXAFEMME, of which the of million SCYNEXIS did ibrexafungerp X,XXX September prescription in tablet, second quarter. launched double $X.X product, reached XXXX, Our and the achieved first XXXX, first nearly commercial

by health to women’s mission and means meet We the in significant beyond. progress we are unmet our excited as today achieving toward work this

Officer, forward. Commercial Christine going Chief our provide Coyne, Our will commercial more details on plans

second in million XXXX in more closed quarter market. launch cash solid quarter than in with support successfully recurrent On the early the refreshed in XXX into $XX And This XXXX. cash million continue in raised the to corporate having April, times commercial XXXX. runway to we challenging expected we cash of have side, our a the the despite first VVC is

programs cash resources a and we Larry our additional open enable the filings hospital on then, session. have complete will Q&A our more We Intern the details regulatory Hoffman, in also will balance. Financial provide to And XXXX. for to Chief expenses our Officer, floor

like I Coyne. our Christine? turn Officer, Chief the would Christine over to Commercial Now, to call

you, Marco, progress. is our this update It to morning on here good wonderful be you Thank morning. to and commercial

As Marco commercial evolving, details. and I share our more excited stated, organization is am to

prescriptions a payer the in and focus are we measures new and Key of on in demand, based coverage. to prescribers, expectations, repeat XX% First, of our significant trending quarter tighter second including sharper in quarter-over-quarter execution, enjoyed according and BREXAFEMME growth XXXX. total growth

address more these detail. in each will We of

I stated, we satisfied. are not As are previously pleased but we

over Given prescribers year we from our all learned that certain the and achieve can we are more. last we their have patients,

created most and approval the have VVC. treatment During VVC More indication campaign. anticipated HCP No our for These continues Say continued up will phase for to the patients this to significant of the of The prepare opportunity of be commercialization, success. of plans set BREXAFEMME for optimize strategies the execution, prevention us enhance and we our

to and have to with of sNDA, and track VVC only VVC, treat first the on the is broadest indication. approval be the anticipated Additionally, BREXAFEMME our prevent therapy will the and both,

broader prescriber wider with will of a expand BREXAFEMME We utility along confidence BREXAFEMME. label expect of that

we have grown quarter quarter-over-quarter. HCPs continually increase In an last of of number over several representing the quarters, prescribers. BREXAFEMME, prescribed Over BREXAFEMME the X,XXX two, XX%

X,XXX prescriptions prescribers of the continue over second continue BREXAFEMME growth XX% XXXX to is solid quarter. over patients. to BREXAFEMME XXXX. focus the our prescriptions first alone, broader expand repeat broadening in range use continue new of of we quarter a grow last Our the of to representing while We generated over a with prescriber quarter

focus more more effective by and of ambition waiting continue solution for over This And regional research patients VVC of field our driven We to the by on to help and that as decades treatment are us establishing of a was representing XX% execution, of boards, the paired messaging. the customers, advisory generic VVC. audit using fluconazole BREXAFEMME sharper growth insights. successfully we track and prescription grow, accountability with more second recent to to wave rapid focused has campaign to and wave gold quarter old their HCP marketing we yield quarter and strengthened coverage relief instead we continue increased By HCPs XXXX, report second of patients competitors. remain HCP continued universe. sales calls In who than disrupting of high XXX new insured of the for commercial our the standard new end garnered they BREXAFEMME and for our intend other these will promotion. on million as use frequency feedback lives, our focused a habit to commercially The

these sharpen HCPs VVC. plans. in BREXAFEMME and motivated We our is fast support by sales within BREXAFEMME to differentiating efforts women and of for prescribing especially will effective value see in execution that its are curing the benefits, Payers to continue to it continue

drivers. shared and More booth campaign. College ACOG, I Obstetricians you During the at campaign May the No The clinical media patient and their premier with of scientific in meeting debuted surround call, our presence Gynecologists, in annual HCP last American Say and with

launched of have an tactics to new hear patient highly XX,XXX clicks site learn increased their digital, one awareness market. search all The to has BREXAFEMME. This advertising website confirms HCP channels, Our June HCP once tactics outperformed patient two. programs ask had have a industry BREXAFEMME, traffic Targeted driving quarter and and campaign multiple in and to about impact competitive advertising further across advertising traffic including HCP and for exceeded treatment their print that in impressions and with patients. industry has generated all benchmarks our in for benchmarks. brexafemme.com media motivated The they XXX,XXX patients day has are HCPs more about paid activation increased a over

are first learn Recently, and but we to explore there traditional the conducted must more we VVC. here. efforts patients our research market topic see our treatment is we to optimize these foray is into results, this patient to outreach, As of delighted with

that Here’s normalizes makes simplicity the interest some this option vaginal confirmation we messaging schedule. the ease and treatment new the yeast received. the plus feedback of Excitement having and prescription about topic infection, for to of yeast the and infection, dosing in campaign efficacy and of discuss the easier it directness a vaginal on

their ask podcast a X This ad additional executing be the expected deliver audience that quarter programs women Looking impressions X.X playing programs exciting HCP These to Winfrey empowering three. we’ll for our new ahead are is custom will patient for Soul Super to in podcast to continue targeted million Oprah include three, to that BREXAFEMME quarter during months. BREXAFEMME. we

and partnered information for for infection while as shelf educate ads across yeast the be over-the-counter and to to over-the-counter will pharmacies HCP yeast We have consumers drive shelf the to Monistat placed local place about are empower both, their and grocery advertisements is This consumers proximal treatments, shopping products. such they infection These display treatments, national will vaginal stores. ask to BREXAFEMME. stores and their seeking BREXAFEMME also country with in initiative built

also BREXAFEMME activate over as treatment other patient who if be effort of will complement of sales National their monitors. maximizing new garner in partners we focused to groundwork the effectiveness Sales video Hulu, rolling will impressions focused on efforts programmatic that increasing This women as SCYNEXIS on and impact. OB/GYN option May, ask brought prescriber We whom in our out be force well and These Director, is for and patient their and on the has the will our waiting HCP right a them. room YouTube million initiative XX placed targeted

are Over we which year, to learned HCPs past prescribe there BREXAFEMME is the where motivated and opportunity. have

to high-value Our will focus HCPs. sales these on continue team

be per sales a need the and grow significant tools large have and quarter-over-quarter. rep unmet of with opportunity number There equipped our continued VVC is We to force necessary and in the optimized targets we’ve to successful.

-- And momentum to going the field ahead. with you update have team forward there I of David. is our We our I leaders sales sales And delighted work leader. the the more call to much and our plan. you. paired solid quarter now into with efforts on turn third I’m to continuing strategic progress. will look a field national and Thank But over the

Thank you, Christine.

We the regulatory and And VVC. recurrent making target we for date as towards accepted and prevention infections. this ibrexafungerp treatment on decision a of our was the was vision granted received supplemental notice a a CANDLE. results announced, prevention submission Phase year, we recently of application progress XXth. multiple review from the positive of priority Earlier NDA continued submitted based fungal study FDA the of for from developing that of November our was have indication X with This

at over As treatment superiority previously significant with Ibrexafungerp key with endpoint Boston, XX.X% presented no RVVC with more reported recently presumed success at including met ibrexafungerp. clinical statistically study ibrexafungerp endpoint, recurrence after also Society all, and Infectious patients. the of primary Disease with suspected, the proven OB/GYN seventy or achieving treated CANDLE XX.X% secondary culture-proven, placebo meeting its recurrence in of in patients of in either non-mycologically detail achieved a in

of the recurrences acute only infections, continues indication product first will approved, the to the its ability treatment is VVC prevention that vaginal for its the of and but BREXAFEMME infections, the treatment yeast ibrexafungerp of is One study this prevent approved activity recurrent be treat attribute not As to oral against in demonstrate ibrexafungerp States disease. and also important If second VVC. fluconazole-resistant treatment United and VVC VVC fluconazole at strains, both, is the only of the only are for fungicidal generating indicated the to CANDLE episode the In the were of treatment, study, on days ibrexafungerp. respond acute prevention one, time and define recurrence. patients an VVC was included patients enrollment. their to needed how fluconazole who study in The acute treated resolved evaluate The to main data episode doses after we better three have patients seven. then of fluconazole three, acute episode to with of failing

Xb the subjects, in in the that persistent XX these challenging a symptoms be the VANQUISH could immunocompromised the upon XX who wide clinical multiple documented However, elimination responded positive resolve population and sub-study. The treatment. a milligrams day and data be within VANISH had to not ibrexafungerp fluconazole including rates This with reduction the to a study trials, States, The a in or to evaluate study treatment addition illustrating included response encompassing We the XX%. ibrexafungerp of cultures observed United And of the The treatment nested this population VVC the XXX from of of VANQUISH after acute further aiming the offered well besides line also subset in positive those fluconazole, the of recently symptoms. in of recurrence patients. will with a treatment signs Favorable was XX treatment, of from trend this populations, from to more enrolled XX is in study Phase to where failure cultures. for we who BID VVC uncomplicated is our announced VVC nested disease in confirmed fluconazole, with persistent patients have failed the centers hope of response of of persistent in study of specific there also data clinical after patients in spectrum broader response reported a patients have subjects. targeting having in VVC with them could that also ibrexafungerp sign sub-study were to and positive expand with to challenging of XXX prevention aimed treatment cases. half was are three single that of included their approximately in with those second as having scenarios clinically did XXXX. conducted such not benefit substantial ibrexafungerp, phase had range in doses the VVC achieving subjects to in majority and complete as ibrexafungerp clinical in one-day single-day ibrexafungerp X these XX% patients after enroll fluconazole a episode patients of

programs our In the addition, we development setting. progress in in continue making hospital

begin have to We study, next FURI and target our of activities soon year. half already in follow-up the of the by cases of will completion all enable enrollment reached XXX of subjects closure study first

XXXX. follow this We data, early Data will of the data review is similar will reporting as and Final timeline. in -- The the guided which -- be Committee by CARES followed will the a the final Review study

has fungal enrolling reminder, patients FURI a other studies are synergia The As Candida evaluating although CARES in patients, and infections. the ibrexafungerp refractory with study and auris continued slowly.

United these ibrexafungerp patients has which many begun invasive well countries MARIO South candidiasis. startup the end already in smaller the The Phase number available to by Also, is guide of X in may study, complete next patients this Africa, study progressing of open sites with We will the are The smaller a process multiple year. study, in planning for and paths. initially and in soon. be development Enrollment sites of analyze open and subjects with evaluating the States than steps other is data than number anticipated, this projected. data will even and potential from

completion previously by the of end of guided, As study we next are year. anticipating

potential the study, the an with an along supportive are data FDA XXXX FURI study first development formulation. later year. MARIO the are with data the indication in formulation the the approval with of after from that this we and be of the an mentioned the paths intended compiling IV discussion completion regarding setting from data for liposomal anticipated a CARES hospital to submission NDA As Also, with study enable previously, Phase in of to for X the ibrexafungerp,

now over And interim to our I turn Officer. We Chief Larry consultation to the Financial end this you. year. of targeting this by Thank call are have will Hoffman,

versus driven million second $XX The increased to increased million cost Total by increased from first the of net of $X.X $X.X XXXX. of of quarter quarter $XX.X the its of second income XXXX quarter increase quarter from commercialization second you, second the total XXXX. quarter to in XXXX XXXX. BREXAFEMME. for XXXX $XXX,XXX the was other of the in recognized for for the second the million of was to $X.X of expense product ongoing expense XXXX. $X.X for other quarter of million for versus $XX.X in income R&D the quarter David. SG&A quarter BREXAFEMME the XXXX second million in revenues Thank of support second million an increase to million

XXXX, second of respectively $XXX,XXX, of $XXX,XXX non-cash on adjustment second fair the of value recognized of value and During gains the warrant quarter the quarter on million $X.X respectively, non-cash of million, liabilities SCYNEXIS XXXX and and gains the derivative liabilities. fair of and $XX.X adjustment

compares plan, totaled That on XXXX in cash upon on the into turn of versus remarks. us Our and anticipated and XX, sales million that final our cash of operating million SCYNEXIS to believes cash his in June $XXX.X over equivalents the million XXXX. December Marco cash for current cash call now and XXXX. and Cash cash quarter XX, the the $XXX.X BREXAFEMME equivalents balance will equivalents existing $XXX.X quarter our Based to fund strong. enable will June on I to its second XX, is XXXX. requirements operating first

Christine you, David. Larry, and Thank

Q&A, successful, open the the We key potential for want working as and reiterate diligently to ibrexafungerp we significant I durable Before profitable at to a SCYNEXIS to call franchise. antifungal few are a points. realize

at in for as net which VVC questions. these brand. a on when We readout generate programs. and progress MARIO, a create alone. with collection PDUFA open a $XXX sales can million U.S. in we of would year additional to in potential taken November leveraged the from to We the hospital the Operator? build updates year, strong a floor $XXX of together, franchise Please believe well be and indications, million and end differentiated as All to recurrent on to CARES XXth FURI date our synergia a have a the plan our planned data data in provide our

comes [Operator of Instructions] Our ahead. the go first Chen Luis Fitzgerald. from question from Cantor line Please

This quarter. Hi. of couple Carvey Congrats Good here. morning, the on questions Cantor. A everyone. Louise from on is for

First, looking in we’re PDUFA forward date November. to your

coverage approaching it’s are launch of Thank from commercial that date, you opportunity it that post targeting almost what the a we market enabling, level much. color year? Also, since highlight approval? will talk Can Secondly, so about of feedback on physician little you bit community? added of end you As by you this the can year the the BREXAFEMME. a additional be been are

This is question. Thank Hi. teams into for physicians our lot recurrent go you helpful much. that Thank for back will opportunity our give field VVC a additional will so indication to Christine. The the data you with of their be them patients. and additional to

heard the me say a are the ones up indication. opportunistic, to probably call after includes most this that that physicians, year RVVC we, target in with prepared and working list have of tightened remarks You our that

is fresh call data for physicians both or always call the and New reps the in fresh. to information helpful, but for sales patients, make bring also the the --

for one So, that’s thing RVVC.

As to we overall it continue say, all, let’s across positive BREXAFEMME intake feedback, feedback to areas. relates get do and very doc

love quickly. the hear from easy-to-use. like doctors. they dosing. as important relief to trial is panels heard pieces, ATU, you too So, very, doc, patient the Dr. hear report love well as see and third-party at look Angulo -- of the as those They I their across reps. And early speak we fact feedback, that usage they BREXAFEMME that. the always they And the do the That’s about unbiased all fungicide reps, perspective and very similar that we one-day They symptom from We the market when research.

of I It’s on channels. sitting of Yes, was us last we Thank million about we’re lives. going And our back So, hear into your Marco. now, is those the coverage? are right things universe. coverage. then, question to percent commercial target And believe on at XX-ish XXXX those XX%. XXX patient all across coming you,

to in the the things ballpark. rank got to So, it, of ahead may be we’re We ground. you but always these

that done help? And so, done. it’s it’s Does not until

so was much. congrats… And super Thank you helpful. It Yes.

no become that think I when after the BREXAFEMME. can fluconazole, repeat there times -- is than many if feedback using can any better years feedback had Maybe don’t see better how if doctor a been to prescribers. XX I add there doctors add, just seeing I they actually prescribing yes, is of multiple

Thank you.

the Thalmann. from ahead. Higgins of next Please question Michael Ladenburg Our from comes line go

behalf This of is the Farhana quarter. Congrats on great Michael. on

questions. two have We

your The you IV is, timing discussions the on X the formulation? the Phase first data one for for bit more a little FDA, could provide with color the of

question. Sure. Thank for is the This you David.

for needed study. put the it right into a enabled toxicology just our were was at very So, this our And all to that particular get formulation abbreviated opinion -- we particular information, our -- understand development completed target were now, the as our study achieve information, we’re that X are positive. able path Phase mentioned, what approval integrated all X this program fast as formulation. drug to The to tolerated. together program I we that a for to together order really our formulation package all path that And this results Phase point, with should putting pieces FDA and all planning really We well for with an study. in that first the be find and/or from be to regular exposure. particular obviously is just along will approval this The in

we progress very regulatory regarding have a be into discussion with good this a path, with are try really new have So, our program rapidly. aiming of to it how development formulation we as formulation. really to have will to to to the with very very have develop previous discussions that’s with in as definition to we to development position soon we at possible, them had that this bring and clear really try productive that a discussion believe the the new And And our pieces data, this intravenous them. certainly, point agencies at

around and was second And can had when of FURI the expect CARES we question from to the studies? say Is safe XXXX? first the -- data we that it top

is submission, the really XXXX, et we guided Well, cetera, in that data and have actually. the

is I FURI with actually mentioned are the wrap as up guided, -- in this So, the there you really we to the study year. of and remaining planning, what towards that’s

study However, that in for their complete could remember to allow patients those obviously long, we FURI patients be and need we treatment. the need the to duration treatment to

have to the of are up before, meetings, during so year. As of to enable at data really available. in from it committee half -- treatment conjunction that wrapping we plan. mentioned the package we data point, try or the start That’s et to current visit activities us data first wrap we’re The committee that data I up information regulatory all we have really going should be next be review to time from everyone its with, in together. aiming order cetera, have that the And data, has that a so all the doing put review -- last to same data that MARIO, that available is can that the together

see we to As we we data an have the guide that really opportunity future, in will, you accelerate sooner if usual, if than will point. can and that, we at

also remind you could the for read do for timing expected that And Thanks. great. out? have just me any you to Okay, when is VANQUISH study,

Yes, do. we

this reinitiating in point VANQUISH for study. the at process are we So, of all the the centers

first means in be -- the the We anticipating is of or months data XX enrollment, sometime when of will data probably that XXXX, about us that it XXXX data will take we’re from that are approximately which the half study. anticipating anticipated

questions. taking for our much Thank great. you Okay, so

the Sure. for Thank you question.

you. Thank

from Please question Wainwright. from of Oren H.C. go ahead. the next comes Our line Livnat

coverage mentioned pharmacy? with you just, these investment could If assistance What on in you then, fluconazole, prior the commercial are at are a women And just just promotion? curious have experience. physician facing the are start but a going we most a have kind from I’m ops also lives I’m get step forward. overall edits of More already with their the experienced good and through I they uh, approval kind Thanks. practices both of -- What copays situation, of experiencing of give with all but sense mentioned continuing pushback perspective, few. XX% or offering, curious Obviously -- you’ve us Say of OB/GYNs fluconazole? about are BREXAFEMME about you just and kind regards No financial to women helping what DTC you of levels prescriptions? can

a podcasting lot follow-up. see of the and we store where talked forward? a separate with I initiatives SG&A trends in You have should about new And going displays,

It’s Great. Christine. question. Thank morning, the for Thank Oren. you you. Good

-- ranges, a in, the copay I lot really have mean, On more many a see we see lot benefit wide data and insurance -- a of carriers we year different designs. we range. a so

pay good, patients Oren, five they copays the all to The our again $XX -- $X of the from majority that do that and that coverage still from from Oren, they will acceptable, right on down is standpoint now, it the what And our have benefit for pocket patients, to that $XX on, range. see the and copay insured, to that kind we And commercially that’s a all So, up with their $XXX. we anything range. design with which out helps we cash that insurance don’t Oren, because $XX card of research not of have is that in way has continuing sensitivity are do copay have have. the of to out-of-pocket card range, formulary, or the or we

So, programs have we those intact. still

same Now, talk about investment about say that here the later, thing but on from advertising, which SG&A an you I’ll asked I’ll standpoint.

these And get year, to to on are of then that to inclusion, get continue Oren, better the payers we sunset. formulary into copay all programs the second things. start you to continuing as increases, commercial the position, with work As

to one? So, SG&A, copay, you’ll see tradeoffs I’ll basically the move on that that. next on help Does

Yes.

guys VVC, we more say your not will indication. job conversations is, ready off on in better or it’s there, and for to access, I so and science getting positioning of national account for quickly, our that in the RVVC get get doors would to us have say, payers say positioned coming are I payers, get getting science would with technology. back to Okay. thing tremendous now. are I done technology you And us interested national have especially the a what one The overall, our bring on guys account always ibrexafungerp, has our also opened RVVC where

you because drug So, should a when put given is that’s a very, I have us. position not that there very for launch. strong This

levels, rolling I got patient year have out in we summer started So, this we in yes, with there. part It’s in advertising. earnest mean, or Investment direct-to-patient. the

in to about and strong saw offices. vaginal two. ready because waiting side, know The about there, the direct more up the to targeted targeted a loop, yeast That’s me that position. BREXAFEMME, see that’s a execution OB/GYNs, on the physician say. talk where prepared how tightening our about new very product in but talking the advertising That was what not position. you is to room there getting it’s patient the based on are because in putting very sitting. can That’s Oren, on waiting good, You doctor quarter patient of and a advertising Sales heard the may remarks your Director room a National infection those called you to patients there, success -- BREXAFEMME audience is talk sitting strong in

us. those focus and continues offices advertising very of National Now, to those very, that Sales the Director our in the for offices, with will same patient rep, be fruitful if put the you in

Now, on the my the consumer remarks. side, prepared word used in I foray

word So, We it used and -- will the about searching I have pharmacies, It shelf they and there on local them they’re BREXAFEMME. pharmacies. these can’t that, right? will in what’s drugstore everywhere. talker. be obviously will called drug stores go and see a and We specific drugstores Monistat, in specific is message they’re of the And someone put national in the looking advertising if for for, aisles in aisle,

that’s because consumer, motivated a a something to So, to got be Oren, But she’s the lead strong thinking it’s in them. really see what doctor, then, aisle and longer because to interesting, connect happens in to then to all a things. see going doctor, there, get to about who’s it’s the call the help Oren, purchasing these

back to you forward look that. I So, to reporting on

we these to see tasks. from results levels think are I going two of differing

So, I successful think they’ll be nonetheless.

obviously because once results what throw return. where see that the want getting reallocation, I what more you the to get like, money will We these, you SG&A are on looks

if think, of what just Christine and best -- can I are expenses, doing relocate in we Oren, Again, are we keeping -- order are if looking -- and it I we to can to jump in, maximize her Right have flat. always -- SG&A in the terms where we the see eventually now, allocate or their team I resources they are returns. planning

improve So, better these we you keep to it the actually we progress. see we flat but we and will ways eventually and SG&A relocate, continue will even SG&A the as at looking to to assess keep initiatives

there feedback it’s All can correct? out awareness think greedy community, time, approval you from don’t of right. I launched the Mycovia’s product? feedback presumably, hearing And of on some is you the if or yet, there with what are initial wondering and any I be I’m are to otherwise regards But KOLs hearing. kind

potential postmenopausal embryo of years. due they permanently due the after almost have it to women drug hysterectomy, interesting, has the only of I very -- the patient fact and know, biologically long treatment, in be termination has a or extremely restricted who of that labeling but patients Mycovia use the on. FDA life, hysterized Mycovia, think for as two toxicity, to you it’s will Actually, limited and body really the of very, are hysterectomy have so half for of with approved been And who the

will VVC And with the approved we this we a have course, in No, all -- product. where available when that addresses the another alternatives on to we indication really The silver actually without of see we available. that the pharmacies So, to lining the fluconazole. limitations fact it’s approval type be I associated also having are don’t has launch. with retail been priced. specialty put expect and lining is there a with and talks that product us But about the risk our the restrictions, and on the now in the offering -- that think product of of will also recurrent Mycovia actually the the this pharmacies. We company been on priced know don’t silver that

I of think thing after a yeast it’s I finally vaginal as the there infection. that, in some XX So, years before, is mentioned innovation good that field

also at have colleagues all the best that are send we’ll Mycovia So, we becoming to that our available. message alternatives the wish

you. Thank

the of from from comes question Brookline next ahead. Our Raja line Kumar Please go Capital Markets.

liposomal will With think interaction how able how with formulation, quickly we the be FDA questions. to trial should start my the and regard you taking to following for a trials? Thanks these the about

quickly, manufacturing cetera, would et are you the is pieces, just have ready. we all say the I reality -- How that that soon soon. going I’m not give to to because

we -- type the really think able anticipating, want study, we need will upon with to after ready discussion them are with contingent the implementation is what first. Phase we to I proper -- X be I’m that. we we that but of will design really them. Phase X/Phase what of And once And are discuss very what X rapidly level trial that start of potentially So with that’s some

product have may healthy So, evaluated so in has volunteers. of -- initial an evaluation far need the to been

really product a number in broader tolerability then bit a to be of information to number having in We sufficient the a safety -- going of see patients and will associated patients the need to to evaluate receiving expand drug. in that little with patients are

of of need that’s in define that product. are, safety be be the orally combined setting, which safety with studies? purpose been with to information in agency. package very, of when they for Will separate assess? ibrexafungerp the what Does the really giving clearly population a what should large all have approach? a X/Phase the in How with the we solid endpoints able package a breach be can already very to have we we together, How been X this we are Phase it very the to discussion two big So, putting to

we are reasonable with to the the development with -- and with able that agency optimistic be path forward. be really are very will And those right the So, that them. reach will hand we we an pieces a to we are discuss efficient it agreement now, of on aiming information have that

SG&A to payer terms what new once negotiations? in year, And SG&A, how BREXAFEMME Thank potentially expansion, gets the regard what And approved for of of we in label that are should indication? the BREXAFEMME with part the for And on you copay are you. setting? the later about also touched think the expectations in expectations of the timelines

ago. for you begun months Hi Kumar, the it’s Thank Payer negotiations question. Christine. have

in our in strengths we’re the directors always with always So, account conversations open conversations, of one out of team national are their the customers. That’s there.

they rest continue molecule. throughout with doing talk this in going that when year next so, going appropriate, information to start ibrexafungerp next. we’re the And about And the into of they’ll Kumar, brought where to

question other correct? it indication, second The was to Kumar on the as SG&A, that relates is

what how are get also expectation to quickly That Yes. this? able the to be have like expanded and you copay terms quickly now, in indication? would terms copay the indications, right -- the of and also in how be get new of XX% Like, know, you there the be what there you’ll you’ll able covered in lives

right? with the so started Yes. conclude going I account conversations to payer see mean, That’s national at guys why have year. will the it, we how is the early the to again, to their in conversations these exactly customers look

to will as think that we aligned I be discussed we the earlier. it copay relates directionally

the indication. out Kumar, how to the treats So, But ahead second well it, molecule. the a see, we’re class. to we’ll It’s love payer exactly again, of wait they have different

strong So, question your we’re on then, And SG&A? really position the a there. last was -- the in

to Yes. the right. new label? have That’s you Like, how expected is change, once that

Yes.

two kind Kumar, of and think, promotion. I indications the for looking between you’re balance the

also in to both representatives discussion, more much indications call sales already doctors. developing valuable So, that really the materials, in field conversation team that so sales which marketing can it a is about the And great the materials have because there’s both have makes of synergy the our the indications. will of lot is the efficient but

totally indication, said one has it’s the treat BREXAFEMME first a but the very infection, only a indication being prevent vaginal Sometimes than you and earlier story, second as about this like treatment get and first nice yeast different we and VVC.

So, the very nice some conversations doctor’s there’ll in office reps. the with be

as that. next the we’ve materials, quarter because stay because these year. now of will right Kumar, in SG&A well the already execute are developing marketing on teams already So, And way first on this it accounted the their is we’ll for

Okay.

we sneak may I going if in, should think to how with COGS? Finally, forward about regard

we goods. for Kumar, Yes, Oh, question. you cost the -- are is of This David. thank

to potentially as continue reducing continue we larger et to our production enhancing to more goods. and have cost imagine, we always, and manufacturing batches, can our batches, and So, opportunity selling are we we finding continue to optimize of more more cetera, ways costs. more And as the you products, are as and our

us clinical so, continue those to to -- together in And the to we that to market. more allowing the bringing continued development, the market really evolving much continue expansion speak, just pieces plus have are down That progressing continue our try will all conditions obviously so COGS. as favorable bringing

more So, get it’s and and I as what right manufacturing we continue really expected to better can now. to only tell you more, better. That’s

much. so Thanks great. Okay,

from of from Our you. Please Securities. the next WBB Instructions] question Brozak line Steve go Thank [Operator comes ahead.

the patient been but answered, that and after for asked imagine that, scripts us I question you had can taking have the just scripts But, Most visits have you got of and more number the with number so and of what questions has I’ve typical questions. would been Thanks of remind number Yes. the do Can would specifically far? refresh And us one have I please. fluconazole. around two.

we the Marco. I -- want are you Did understand question, you… to sure make

I shown have requiring three, five we if patients can actually patients actually our prescriptions. start. that XX% prescription. you in shown have about even about more a Yes, four, Steve, some of prescription we of receiving the as material or they XX% time, of of need another over actually fluconazole, And have

additional prescriptions visits of will require doctor. many repeat course, these to also Of a

to clearly fungicidal where are not the concerns far patients major has treatment. you action, candidate with of the the again have its is like been BREXAFEMME, that mechanism of one a think some so I fluconazole survive of due one highlighting and will probably treatment fungistatic the So, that you of which

grow again, Of course, has can a it start because then improvement patients completely feel but short-term killed. not may have been to

ask with pleased that very I of treatment the doctors think a are the probably you point. why I one really have is have been now, has about to very the good been So, that reasons who this raising And and BREXAFEMME. of think fluconazole BREXAFEMME. maybe from what failures of use multiple Christine to see issue feedback this And I would the doctors patients

What course, the while Hi, come is It’s that. so feeling we’ve Steve. for for been Christine. either. for patients now good they -- And, patient them of their back. Yes. doctors from much the like the a discussing of to we’re hearing Thank you see is not doctor. kind don’t great isn’t It’s for what

the physicians that the product so, they excited in back see or early helps The callbacks either, symptom been they not coming Marco, patients are to is or are BREXAFEMME patients They And for point, additional getting have happy. about your situation the what relief. else. and that with that something

or is have the will other do I you like a don’t option, The the what and gives because thing to about this not when of I it said, sense it see say, what early them Marco, talked we in customers an which you fluconazole is, physician our you with have, be may launch, left optimal customers you’re relief solution. others

And own give had for patients something couldn’t because degrees else. so, they their them physicians of discomfort anxiety and the

to that. alleviate helped So, BREXAFEMME has

a response. been positive very that’s So,

have patients, imagine economics David this to XX% patients if add received in they both some doctors, because more doses of course times important their creates, by they I’d you frustration can BREXAFEMME the And, is see multiple patients. point numbers Christine. who is fact to makes, we patients times and X patients BREXAFEMME. of as finally people respond And finally this, that shown remind in the you, three issue, Patients, way, now not fluconazole, fluconazole, in which the coming their well that these the problem really I the the doctors, also reduced single-day can doctors; is is see of and able a back data that issue patients health times because this than Steve, for they of to fluconazole, CANDLE for hard who multiple and three because also good clearly dose satisfies of same is one responded -- patients payers like as with study the address did they Thank addressed; payers. and another with failed is the by doses the of actually to of approved fluconazole, don’t

VANQUISH So, that further solution patients also -- even new designed address that with to to who study are and specifically good well-designed a confirm will believe larger, is this expect the we a question we for have fluconazole. data in to BREXAFEMME now I responding show we study, that not to

like the Because start And Oprah their detail. of carryall made the medicine? and a back that things those What what And things see have level? obviously any? there, spectrum, an of Thank side practical appreciate queue. into to concierge around personal, and you. it’s is on other question, Last audience your I’ll I the thoughts hop that? have approach answer going inroads a taking around care clinicians like fascinating, if -- that are are of what have on you more patients on I with but what focused your do the and where you of been one inroads kind your out more there taking thoughts their

strengths mindful be our I really their them. would evaluation I time their where Oren, we return said you to there. as this to to Steve. them. I put have is verticals, of looked very And I few interesting and of think is What There’s make earlier, marketing to at say they continues they’re Thanks, a talking to, at was do Yes. Yes. the and sure our money have team them has we

not So, tool of if something obviously, yet. hear say us, you’ll be to evaluation Steve, as continued to is a is at And it, but Thank complete becomes that on for us this it our I that you. would speak point. of you,

comments. like and I to closing Thank session. Marco question-and-answer we of the end Taglietti have Mr. you, reached gentlemen, to over conference now ladies the would the turn for

continue because of a overall of to brief I brief very just the just you to franchise. that of of Operator? you BREXAFEMME for potential plans. our we much, Thank optimistic our remain about listening a first much, achieve becoming the teleconference. we of have everyone will statement SCYNEXIS course, and very Thank wonderful actually have a resources everyone, to to we long-lasting day. of remain optimistic very about -- make important one very future the all, And and ibrexafungerp antifungal

you. for Thank you has sir. your concluded. participation. now Thank you, Thank The conference

You disconnect your may all lines.